Trial Details
COMPLETEDBasic Information
| Clinical ID | c1547 |
|---|---|
| Identifier | NCT03695185 |
| Trial Title | A Study to Investigate How Well Ravagalimab (ABBV-323) Works and How Safe it is in Participants With Moderate to Severe Ulcerative Colitis Who Failed Prior Therapy |
| Trial URL | Visit Original Page |
Study Information
| Study Results | YES |
|---|---|
| Conditions | Ulcerative Colitis (UC) |
| Interventions | DRUG: Ravagalimab 600 mg|DRUG: Ravagalimab 300 mg |
Participant Information
| Sponsor | AbbVie |
|---|---|
| City | Tucson |
| Country/Region | United States |
Enrollment Criteria
| Sex Requirement | ALL |
|---|---|
| Age Requirement | ADULT, OLDER_ADULT |
Study Design
| Study Type | INTERVENTIONAL |
|---|---|
| Phase | PHASE2 |
Time Information
| Start Date | 2019-03-26 |
|---|---|
| Primary Completion Date | 2021-04-05 |
| Completion Date | 2022-01-10 |